PrEP Adherence Monitoring Using Dried Blood Spots

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
Indications HIV infections
Focus Pharmacokinetics; Therapeutic Use
Acronyms DOT-DBS

Most Recent Events

02 Sep 2021 Results of two studies (DOT-DBS and TAF-DBS) assessing to mimic low, medium, and high adherence, published in the AIDS.
24 Sep 2018 Results published in the AIDS.
12 Jul 2018 Results evaluating whether tenofovir hair concentrations differ between women and men receiving directly-observed TDF/FTC published in the AIDS

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight